Buprenorphine Hydrochloride

CHEMBL2368861 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

504.1 g/mol

LogP

—

Phase

4

The hydrochloride salt of buprenorphine, used to treat opioid dependence and chronic pain. It is available in sublingual, buccal, transdermal, and injectable formulations. Its partial agonist activity at mu-opioid receptors provides pain relief and reduces withdrawal while limiting abuse potential.

Molecular Weight

504.1000 g/mol

TPSA

62.20 Å²

Therapeutic Areas

Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Pain Colorectal Cancer Generalized Anxiety Disorder Hepatitis C HIV/AIDS Insomnia Major Depressive Disorder Non-Small Cell Lung Cancer Obesity Ovarian Cancer Pain Management Pancreatic Cancer Prostate Cancer Psychiatry Rheumatoid Arthritis Schizophrenia Thyroid Cancer

Mechanism of Action

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl

InChI

InChI=1S/C29H41NO4.ClH/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28;/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3;1H/t20-,21-,24-,26+,27-,28+,29+;/m1./s1

Molecular Formula

C29H42ClNO4

HBD / HBA

3 / 5

Rotatable Bonds

5

Heavy Atoms

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

The hydrochloride salt of buprenorphine, used to treat opioid dependence and chronic pain. It is available in sublingual, buccal, transdermal, and injectable formulations. Its partial agonist activity at mu-opioid receptors provides pain relief and reduces withdrawal while limiting abuse potential.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Buprenorphine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2368861. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3033050. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Buprenorphine Hydrochloride on PillFYI

Structure

Quick Data

Formula: C29H42ClNO4
Synonyms: 5

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.